DURHAM, N.C. — Phase Bioscience, a startup focused on purification of biotherapeutics also known as PhaseBio, is licensing technology from Duke University for use in drug delivery.
Financial terms were not disclosed.
The agreement will enable PhaseBio to expand its research efforts into possible means of treating certain forms of cancer.
The Duke technology centers on a process called ELP, or elastin-like polypeptides.
According to PhaseBio’s web site: “ELPs have been designed to undergo an inverse phase transition in solution in response to a change in solution conditions. For example, ELPs are highly soluble in water below the transition temperature but, when heated, undergo a rapid phase transition over a narrow temperature range.”
“The ELP technology has the potential to deliver products with greater efficacy and lower side effects,” said Gabriel Cipau, PhaseBio’s chief executive officer. “PhaseBio’s strategy is to form research agreements with leading pharmaceutical and biopharmaceutical corporations, while continuing the development of the technology for drug delivery for its own portfolio of products.”
PhaseBio’s proprietary deltaPhase System is a production technology for purification of peptides and proteins.